Investigational drug · Phase 3
NXT007
Also called: Zemocimig, RO7589655, RG6512
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hemophilia A.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "NXT007"
First trial start
2023
Sep 21, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NXT007", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hemophilia A
Approved drugs for the same conditions: Hemophilia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "NXT007" as an intervention, largest first.
- A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia APivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07416604 · 360 participants (planned) · Start Apr 27, 2026 · Primary completion Feb 29, 2028
Drug: Emicizumab · For: Hemophilia A
Sites: Orange, California; Aurora, Colorado; Miami, Florida · 63 sites in all
- A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia APivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07416526 · 138 participants (planned) · Start May 15, 2026 · Primary completion Sep 23, 2027
Drug: Human Coagulation Factor VIII · For: Hemophilia A
Sites: Aurora, Colorado; Iowa City, Iowa; Godoy Cruz, Argentina · 36 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05987449 · 60 participants (planned) · Start Sep 21, 2023 · Primary completion Dec 11, 2033
Drug: NXT007 · For: Hemophilia A
Sites: Sacramento, California; Washington D.C., District of Columbia; Indianapolis, Indiana · 14 sites in all
- Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and ChildrenPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07838194 · 50 participants (planned) · Start Nov 30, 2026 · Primary completion Sep 30, 2028
Drug: NXT007 · For: Hemophilia A
Sites: Kawasaki-Shi, Japan
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06189508 · 48 participants · Start Feb 14, 2024 · Primary completion Dec 22, 2024
Drug: NXT007 · For: Healthy Male Participants
Sites: Auckland, New Zealand; Christchurch, New Zealand
Newest research
PubMed records naming it or its code names, newest first.
- Mechanism of action and impact on thrombin generation of denecimig (Mim8), emicizumab, and zemocimig (NXT007): comparative analysis using sequence-identical analogs.
Lund J, Egebjerg T, Bjelke JR, et al. · Res Pract Thromb Haemost 2026
- NXTAGE: a phase 1/2 study of NXT007 to assess safety, pharmacokinetics, and efficacy in hemophilia A without inhibitors.
Nogami K, You CW, Park YS, et al. · Blood 2026
- FVIIIa Mimetics: New Approaches and Next-Generation Initiatives.
Matsushita T, Nogami K, Shanmukhaiah C · Haemophilia 2026
- Factor-VIII mimetic bispecific antibodies for the treatment of hemophilia A: an update.
Eduarda Alves de Jesus V, Lamounier de Almeida D, Muniz Júnior RL, et al. · Expert Rev Clin Pharmacol 2026
- Next-generation FVIIIa-mimetic bispecific antibody NXT007: evaluation in preclinical models of hemostasis and thrombosis.
Locke M, Albiez J, Receveur N, et al. · Blood Adv 2026
- NXT007 enhances in vitro coagulation potential in the coexistence of emicizumab in hemophilia A through distinct complex formation.
Yamaguchi K, Haraya K, Koga H, et al. · Res Pract Thromb Haemost 2025
Also in development for Hemophilia A
- SR604Phase 34 trials
Shanghai RAAS Blood Products Co., Ltd. · Factor VII Deficiency, Hemophilia A, Hemophilia B
- BIVV001efanesoctocog, AltuvoctPhase 33 trials
Swedish Orphan Biovitrum · Haemophilia A (Moderate or Severe), Hemophilia A, Hemophilia A, Severe
- GS1191-0445Phase 32 trials
Gritgen Therapeutics Co., Ltd. · Severe Hemophilia A, Hemophilia A
- Valoctocogene roxaparvovecBMN 270, GENEr8Phase 32 trials
BioMarin · Hemophilia A, Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII
- ARD001Phase 21 trial
Arditus Pte Ltd · Hemophilia A, Healthy Adult Participants
- ASC618Phase 21 trial
ASC Therapeutics · Hemophilia A
- BAY2599023DTX201Phase 21 trial
Bayer · Hemophilia A
- SPK-8011QQRO7878488Phase 21 trial
Roche (Genentech) · Hemophilia A
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.